ArticleThe Journal of experimental medicine1996
Heterogeneity among Ly-49C natural killer (NK) cells: characterization of highly related receptors with differing functions and expression patterns.
Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 114 citations in OpenAlex.
- Ly49G, but not Ly49C/I, is dispensable for diverse antigen-specific memory NK cell responses in H-2d and H-2b mice.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Imprint of Initial Education and Loss of Ly49C/I in Activated Natural Killer Cells of TAP1-KO and C57BL/6 Wildtype Mice.Frontiers in immunology · 2022Article
- Control of Viral Infection by Natural Killer Cell Inhibitory Receptors.Cell reports · 2020Article
- Analysis of Ly49 gene transcripts in mature NK cells supports a role for the Pro1 element in gene activation, not gene expression.Genes and immunity · 2016Article
- Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control.Frontiers in immunology · 2016Review
- Ly49C-dependent control of MCMV Infection by NK cells is cis-regulated by MHC Class I molecules.PLoS pathogens · 2014Article
- The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation.Immunity · 2012Article
- Cytomegalovirus immunoevasin reveals the physiological role of "missing self" recognition in natural killer cell dependent virus control in vivo.The Journal of experimental medicine · 2010Article
- Evidence for high bi-allelic expression of activating Ly49 receptors.Nucleic acids research · 2009Article
- Article
- Complete elucidation of a minimal class I MHC natural killer cell receptor haplotype.Genes and immunity · 2005Article
- Concerted and birth-and-death evolution of multigene families.Annual review of genetics · 2005Review
- Ly49Q, a member of the Ly49 family that is selectively expressed on myeloid lineage cells and involved in regulation of cytoskeletal architecture.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Receptor/ligand avidity determines the capacity of Ly49 inhibitory receptors to interfere with T-cell receptor-mediated activation.Immunology · 2003Article
- Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match.Genes and immunity · 2002Review
- Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H.The Journal of experimental medicine · 2001Article
- Ly49 gene expression in different inbred mouse strains.Immunologic research · 2000Review
- The natural killer gene complex genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Acquisition of Ly49 receptor expression by developing natural killer cells.The Journal of experimental medicine · 1998Article
- Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene.The Journal of experimental medicine · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ly-49C is a member of the polymorphic family of murine NK cell inhibitory receptors. The 5E6 antibody that defines a subset of NK cells responsible for the rejection of parental H-2d bone marrow by F1 mice has been shown previously to react with Ly-49C. Here, the 5E6 antibody was found to detect two Ly-49C-related molecules in B6 mice. Two cDNA clones were isolated from B6 NK cells, one identical to previously reported Ly-49CB6 and the other a novel cDNA. The deduced amino acid sequence of the latter differs from that of Ly-49CBALB at only 4 residues, whereas the previously reported Ly-49CB6 differs at 22 residues. Flow cytometric analyses of COS cells transfected with the two cDNAs showed that the 5E6 antibody binds to both Ly-49 molecules, while another anti-Ly-49C antibody, 4LO3311, binds to the newly described Ly-49C but not the previously reported Ly-49CB6. Two-color flow cytometric analysis detected 5E6+4LO3311- as well as 5E6+4LO3311+ subsets of NK cells from B6, but not BALB/c, mice. The level of Ly-49C expression on B6 NK cells detected by the 4LO3311 antibody was substantially lower than that on BALB/c NK cells. Binding specificity of the novel Ly-49CB6 was indistinguishable from that of Ly-49CBALB, whereas no binding was detectable with previously reported Ly-49CB6. These results demonstrate that the newly described Ly-49CB6, not the previously reported Ly-49CB6, is the probable B6 allelic form of Ly-49C. The previously reported Ly-49CB6 must be encoded by a separate gene and should be renamed Ly-49I. The implication of these results with respect to the role of Ly-49C in hybrid resistance is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.